Safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib (Infanrix-IPV/Hib) in infants

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001513-27

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the safety and reactogenicity of the study vaccine administered as a three-dose primary vaccination course.


Critère d'inclusion

  • Healthy volunteers (Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases)

Liens